Atlas Trials

First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects

Clinical trial NCT03912441 · COMPLETED

Trial details

NCT number
NCT03912441
Sponsor
Biocad
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2019-01-30
Primary completion
2019-09-30
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.